Advertisement
BEFORE YOU BEGIN
• Contact Information
• Username and Password
• Author Checklist
• Downloadable Forms
• Submission declaration and verification
• Guide to Uploading Files
• Copyright
• Use of inclusive language
• Reporting on Race and Ethnicity
• Open access
PREPARATION
• Abbreviations/Acronyms and Use of the Active Voice
• Abstract
• Key Words
• AAO Meeting Papers and Posters
• Acknowledgments
• Astigmatism Reporting
• Authorship
• Cancer Classifications
• Clinical Trials and Clinical Trial Registration
• Conflict of Interest (financial disclosure)
• Publication Ethics
• Copyright
• Correspondence and Replies
• Cover Letter
• Drug and Equipment Names
• Editorials
• English Editing Assistance
• Figures
• Financial Support
• Institutional Review Board
• Legends
• Manuscript Text Format
• Online Supplemental Materials
• Permission to Use Copyrighted Materials
• Précis
• Preprint Server
• Prior and Repetitive Publication; Plagiarism
• Precedence
• Reference Format
• Reports
• Review Articles
• Translational Science Reviews
• Statistics
• Study Design
• Tables
• Video Clips
REVIEW PROCESS
• Review and Publication Process
• Revision Submission
• Rejection of Manuscripts
• Data visualization
• Research Data and Data Sharing
AFTER ACCEPTANCE
• Proofs
• Reprints
• Cover Figures
• In Press/Online Release
AUTHOR INQUIRIES

To submit a manuscript please go to https://www.editorialmanager.com/XOPS/default.aspx. This site is also available through http://www.ophthalmologyscience.org/.




Submission Types

Submissions are categorized into the Article Types listed below. Please select the appropriate Article Type to start the submission.

  • Manuscripts – A standard submission; a manuscript that does not fall into any of the following categories:
  • AAO Meeting Paper – A manuscript based on material that has or will be presented at an American Academy of Ophthalmology Annual Meeting. Ophthalmology Science has the right of first refusal on materials presented at the Academy's annual meetings.
  • Correspondence – Comments by readers about articles that posted online and published in Ophthalmology Science within 8 months. Please see specific criteria for submission in the Correspondence section of this Guide.
  • Editorial – Typically by invitation from the Editor-in-Chief or Section Editor. Please see specific criteria for submission in the Editorial section of this Guide.
  • Systematic Review or Meta-analysis – Please see specific criteria for submission in the Systematic Review/ Meta-analysis in this Guide.
  • Translational Science Reviews – Typically by invitation from the Editorial Board. Please see specific criteria for submission in the Translational Science Reviews section of this Guide.
  • Report-Invited –Typically by invitation from the Editorial Board. Please see specific criteria for submission in the Reports section of this Guide.


Contact Information

If you have questions about the submission process, please contact the Editorial Office by email at [email protected] or by phone at 415-447-0261. If you are having trouble logging in to Editorial Manager, please visit https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/kw/editorial+manager/ for more information or contact [email protected].

Communication about manuscripts occurs primarily through email and only with corresponding authors, so it is important for authors to keep their contact information (address, institution, phone numbers, and email address) current in Editorial Manager.

Username and Password

Editorial Manager is used for processing all submissions and relies on correct e-mail addresses for all authors and reviewers. Your username and password are the same regardless of your role as author or reviewer.

Duplicate registrations create substantial problems, such as authors unable to access invitations to revise or reviewers unable to access review invitations. Please follow the steps below to update important information. Be sure to save any changes by clicking “Update” or “Submit” as appropriate before exiting. Please do not register a second time, if you believe your information is already in the system.

IF YOU KNOW YOUR USERNAME AND PASSWORD:
  1. Log into the home page https://www.editorialmanager.com/XOPS/default.aspx using your username and password and hit enter or click “Author Login”
  2. Click “Update My Information” in the top left corner of the screen and review your contact information. Only one e-mail address can be listed. Please be sure you use an e-mail that you frequently check and is the least likely to change should you relocate to a new institution. Here you can update all your current contact information and change your password. Please remember to click “Submit” to save changes before closing the window.
  3. Change data as needed – Be sure to click “Submit” on the bottom of the page.


  4. We greatly appreciate you taking the time to update your information.

    If you do not know your username and password but believe you are in the system, please do the following:
  5. Go to Editorial Manager https://www.editorialmanager.com/XOPS/default.aspx
  6. Click on “Send Login Details” and enter your e-mail address you believe to be registered in the system. If you are already in the system, it will notify you via e-mail to reset your password.
  7. If you have changed your e-mail address recently and Editorial Manager does not recognize you, we suggest you also try entering in your previous e-mail address so that you do not generate duplicate registrations within the system.


  8. If you have never registered as an author or reviewer:
  9. If you have never been in the system in any role (author or reviewer) go to the home page at https://www.editorialmanager.com/XOPS/default.aspx click on “Register Now” and follow the steps provided on the website.


If for any reason you cannot access your information or are not sure if you are in the system, please send an e-mail to [email protected] with your first name, last name, city and state or city and country as appropriate and your new e-mail address. The Editorial Office can verify if you have an existing account.

Author Checklist

Please prepare the following items prior to logging into Editorial Manager:
  • ___ Designate one author as the corresponding author with contact details.
  • ___ If the paper was previously rejected by another journal, please prepare and submit copies of the reviews and your responses to them in the Cover Letter.
  • ___ Provide at least 4-12 taxonomy topics on the submission form.


When uploading files, please make certain that:
  • ___ Précis is 35 words or fewer, acronyms spelled out, written in full sentences rather than a bulleted list, and upload as the “Precis” file.
  • ___ Manuscript file contains a title page.
  • ___ Manuscript file contains an abstract.
  • ___ Manuscript file contains continuous line numbering.
  • ___ Figures and tables are not embedded in the manuscript file; submit figures and tables as separate files.
  • ___ Abstract conforms to the journal’s structured format.
  • ___ Figures are in tiff or eps format.
  • ___ Tables include titles, brief description, and footnotes.

Acceptable File types are used (https://www.elsevier.com/__data/promis_misc/OPHTHA_Listofacceptablefiletypes.docx).

Further considerations:
  • ___ Use the active voice when writing the manuscript.
  • ___ Spell out acronyms.
  • ___ Spell-check and grammar-check your manuscript prior to submission.
  • ___ Ensure that references are in the correct AMA style format.
  • ___ Make certain that all references are cited in the text.
  • ___ Obtain permission for use of copyrighted material from other sources.
  • ___ Upload written permission from person(s) mentioned in the acknowledgment section


Downloadable Forms



Contributorship Form

ICMJE Conflict of Interest/Financial Disclosure

Reviewers

CME Credit Request for Manuscript Review

Other

CONSORT Agreement for a Randomized Controlled Trial

Cover Art Copyright Assignment

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

Elsevier supports responsible sharing

Find out how you can share your research published in Elsevier journals.

Guide to Uploading Files

Once files are uploaded, please place them in the correct order for the submission PDF by clicking the “Update File Order” button. The system will create a PDF of your uploaded files for your approval before completing the submission. If necessary, you may exit the system and return to approve the submission at your convenience. Please review your submission and approve it, or, if necessary, make corrections and repeat the process until you are satisfied. Incorrect file formats, long file names, or missing components will prevent the PDF of your submission from building. If any changes are required to the uploaded files, you will need to remove the original file and upload a new file with your corrections. Changes cannot be made to files once they have been uploaded into the system. At the last step, when you are ready to approve the submission and click “Approve Submission” you must also agree to the Ethics in Publishing statement. A link is provided to the statement and you agree to it by checking the box.

A Manuscript Number will be assigned during the submission process. Please use this number in all communications regarding your submission.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult https://www.elsevier.com/about/policies/copyright/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult https://www.elsevier.com/about/policies/copyright/permissions.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. For more information see https://www.elsevier.com/copyright.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about these agreements please visit https://www.elsevier.com/fundingbodies

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Open Access

This journal is fully open access; all articles will be immediately and permanently free for everyone to read and download. Permitted third party (re)use is defined by the following Creative Commons user licenses:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article. If you need to comply with your funding body policy with a CC-BY license, you can apply for the CC-BY license after your manuscript is accepted for publication.

For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to the American Academy of Ophthalmology, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

To provide open access, this Journal has a publication fee (also known as an article publishing charge APC) which needs to be met by the authors or their research funders. There is a discounted fee for members of the American Academy of Ophthalmology. Learn more about Elsevier's pricing policy: https://www.elsevier.com/journals/ophthalmology-science/2666-9145/open-access-journal.

All authors who are eligible for a Research4Life Article Publishing Charge (APC) waiver or 50% discount will automatically see information after acceptance of their article in the rights and access forms informing them about the APC waiver or discount depending on their eligibility criteria. More information on the Research 4 Life open access eligibility program is available here.

For information about joining the American Academy of Ophthalmology, visit https://www.aao.org/member-services/join

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Reporting on Race and Ethnicity

Ophthalmology Science encourages adoption of the guidelines outlined in the AMA Manual of Style, and updated in https://jamanetwork.com/journals/jama/fullarticle/2783090. This includes acknowledgement that race and ethnicity are cultural constructs with biological contribution through genetic heritage, but do not have well defined nor clear scientific meaning. The names of races and ethnicities should be capitalized, and should be used in adjectival form rather than as nouns. Methods for the assignment of category should be specified, and justification for the inclusion of race and ethnicity in data collection and analysis should be clear.

Open access

Please visit our Open Access page for more information.




Abbreviations/Acronyms and Use of the Active Voice

Please refer to the AMA Manual of Style for a listing of acceptable abbreviations and acronyms.

On the title page, please define any abbreviations and acronyms that are used in the manuscript. If the manuscript is accepted, this list will be included on the last page of the article in the footnotes as a convenience for readers.

Please be sure all abbreviations/acronyms are spelled out at first use in the abstract and again at first use in the text. An abbreviation/acronym should appear first in parentheses immediately after the term or phrase to which it refers. Every abbreviation used in any table or figure should be defined in each corresponding legend.

When writing the manuscript, use the active voice whenever possible.

Abstract

A structured abstract is required for Manuscripts, AAO Meeting Papers, and Systematic Reviews or Meta-analyses.

For Reports only: A 35-word unstructured abstract is required for editors'/reviewers' view only and will not publish with the report. Please submit the 35-word unstructured abstract on the online submission form field labelled “abstract.”

Abstracts for Manuscripts, AAO Meeting Papers should not exceed 350 words and should be submitted on a separate page in the manuscript file. Deletion of any required section of the abstract must be justified in the author cover letter. The following 7 sections must appear in the abstract; please select the most appropriate heading for each section (for example, chose either “Objective” or “Purpose” for the first section):
  1. Objective or Purpose: Concisely state the study goal.
  2. Design: Identify the study design using a phrase such as cross-sectional study, clinical trial, cohort study, etc. Study design types are summarized in the Study Design section of this guide. The CONSORT Worksheet is required for randomized controlled trials.
  3. Subjects, Participants, and/or Controls: Describe the persons or eyes studied and the controls if a separate control group is included.
  4. Methods, Intervention, or Testing: Describe the principal treatment(s), procedure(s), test(s), or observation(s) performed.
  5. Main Outcome Measures: Define the main parameter(s) being measured (e.g., intraocular pressure, visual acuity, degree of inflammation, etc.)
  6. Results: Summarize the principal measurements (data) obtained. The order should reflect the purpose and design, and the strength of the findings should be appropriately conveyed.
  7. Conclusions: State the conclusion(s) derived from the data analysis.


Abstracts for Systematic Reviews or Meta-Analyses should not exceed 350 words and must include 5 sections following the PRISMA guidelines (PRISMA Checklist: http://prisma-statement.org/documents/PRISMA%202009%20checklist.doc; and PRISMA flow diagram: http://prisma-statement.org/documents/PRISMA%202009%20flow%20diagram.doc). At a minimum, the systematic review should have been prospectively registered (e.g., in PROSPERO: https://www.crd.york.ac.uk/PROSPERO/). The registration number should be included in both the abstract and text.
  1. Topic: Provide an explicit statement of the specific clinical question being addressed with reference to a brief description of the participants, interventions (or exposures), comparators, and outcomes examined.
  2. Clinical relevance: Characterize the magnitude and importance of the condition; when relevant, define the current standard of care.
  3. Methods: Describe the key eligibility criteria for including studies in the systematic review, key databases searched and search dates, and methods of assessing the risk of bias in the individual studies.
  4. Results: Summarize the number and type of included studies and participants, and relevant characteristics of studies; describe the results of main outcomes (benefits and harms), preferably indicating the number of studies and participants for each. If a meta-analysis was done, include summary measures and confidence intervals; report the direction of the effect or association (i.e., which group is favored) and size of the effect using language meaningful to clinicians and patients.
  5. Conclusion: Summarize the strengths and limitations of the evidence, your general interpretation of the results, and important implications.


Abstracts for Translational Science Reviews are unstructured and should not exceed 350 words.

Key Words

On the title page, please add 3 to 5 key words to the manuscript. If the manuscript is accepted, this list will be included on the last page of the article in the footnotes section as a convenience for readers and to improve searchability online.

AAO Meeting Papers and Posters

Ophthalmology Science has the right of first refusal to any manuscript or Report (see the Report section) derived from a presentation at the American Academy of Ophthalmology Annual Meeting. Presentations at the Academy's subspecialty day programs are exempt from this requirement (although submissions from such presentations are welcome). Authors seeking publication may submit their manuscript in full or Report length (without requesting invitation) to the journal before, during, or after the Annual Meeting presentation. Please note on the cover page of the submission that it is derived from an Annual Meeting paper or poster. For full-length manuscripts, please be sure to select “AAO Meeting Paper” for the “Manuscript Category” please do not use “Manuscript” in these instances. For Reports, please select “Report-unsolicited” for the “Manuscript Category.” A full-length manuscript or Report based on a presentation at the AAO Annual Meeting can be submitted to other journals if Ophthalmology Science declines to accept it after receipt (as documented by a rejection letter from the journal office) or if a waiver is granted in writing by the Editor-in-Chief.

General inquiries about the Academy annual meeting abstract submission may be sent to [email protected].

Acknowledgments

The journal requires acknowledgment of anyone who makes substantial contributions to a manuscript but does not qualify as an author. Please refer to the Authorship section of this guide, specifically regarding Ghost/Guest Authors. The journal does not allow ghost authors.

The journal will also acknowledge those who reviewed, discussed, edited scientific content, referred patients, translated references, provided extensive statistical assistance, or provided essential tissue, equipment, or other materials without which the study could not have been completed. (See: Lichter PR. The author wishes to thank. Ophthalmology. 1988;95:293-4). In such cases, written permission from the person being acknowledged is required.

The journal does not print acknowledgments for those who participated in studies (e.g., patients), those who edited for grammar or formatting, or those who provided “helpful” or “moral” support or similar collegial aid to the authors. The journal does not publish acknowledgments of individuals whose service as employees contributed to a study, e.g., administrative assistants, clinic coordinators, technicians, ophthalmic photographers, or technologists.

Astigmatism Reporting

Reporting Refractive Surgery Outcomes and Astigmatism Without Lens Removal Surgery: Descriptions of astigmatism should adhere to terminology and graphical representations originally described by Alpins (references 1-3) and include graphs described by Waring (reference 4-6). Editorials by Reinstein et al (reference 7-8) present the argument for standardization.

When reporting refractive surgery outcomes, please include 6 graphs to illustrate the following:

  1. Uncorrected distance visual acuity
  2. Change in corrected distance visual acuity
  3. Spherical equivalent (attempted versus achieved)
  4. Spherical equivalent refractive accuracy
  5. Spherical equivalent refraction stability
  6. Refractive astigmatism


Reporting Refractive Surgery Outcomes and Astigmatism With Lens Removal Surgery: If the manuscript is analyzing refractive outcomes after lens removal surgery (cataract or refractive lens exchange), the refractive cylinder is influenced by both the IOL and the corneal incision, and therefore these have to be analyzed independently. For separate analysis of the astigmatic effect of the corneal incision, these 4 factors should be considered:

  1. Location of the incision site with respective to steep meridian for all the patients in the study.
  2. Histogram of the change in preoperative vs postoperative corneal astigmatism.
  3. The mean magnitude (and standard deviation, minimum, maximum) of the flattening effect of the corneal incision to provide the astigmatic change at the meridian of the incision.
  4. The mean magnitude (and standard deviation, minimum, maximum) of the surgically induced astigmatism (SIA) vector to provide the total astigmatic change, including both the flattening and torque effects.


When reporting refractive surgery outcomes, please include 4 graphs to illustrate the following:

  1. Postoperative uncorrected distance visual acuity and postoperative corrective distance visual acuity
  2. Difference between postoperative uncorrected distance vs postoperative corrected distance visual acuity
  3. Postoperative spherical equivalent refraction compared to the intended target refraction (Spherical equivalent refractive accuracy)
  4. Postoperative Refractive cylinder


References

  1. Alpins NA. A new method of analyzing vectors for changes in astigmatism. J Cataract Refract Surg. 1993;19:524-533.
  2. Alpins NA. Vector analysis of astigmatism changes by flattening, steepening, and torque. J Cataract Refract Surg. 1997;23:1503-1514.
  3. Alpins N. Astigmatism analysis by the Alpins method. J Cataract Refract Surg. 2001;27:31-49.
  4. Waring GO III. Standard graphs for reporting refractive surgery. J Refract Surg. 2000;16:459-466. Erratum in J Refract Surg. 2001;17:following table of contents.
  5. Reinstein DZ, Waring GO III. Graphic reporting of outcomes of refractive surgery. J Refract Surg. 2009;5:975-978.
  6. Waring GO III, Reinstein DZ, Dupps WJ, et al. Standardized graphs and terms for refractive surgery results. J Refract Surg. 2011;27:7-Erratum in J Refract Surg. 2011;27:88.
  7. Reinstein DZ, Archer TJ, Randleman JB. JRS standard for reporting astigmatism outcomes of refractive surgery. J Refract Surg. 2014;30:654-659.
  8. Reinstein DZ, Archer TJ, Srinivasan S, et al. Standard for reporting refractive outcomes of intraocular lens-based refractive surgery. J Cataract Refract Surg. 2017;43(4):435-439.


Authorship



Authorship Criteria

The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (http://www.icmje.org/) for authorship. Each author must meet criteria for Authorship. The ICMJE recommends that authorship be based on the following 4 criteria:
  1. Substantial contributions to conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  2. Drafting the work or revising it critically for important intellectual content; AND
  3. Final approval of the version to be published; AND
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


It is the responsibility of the corresponding author to confirm that each coauthor meets the requirements for authorship. These ICMJE forms should be uploaded during the revision stage; each co-author must submit an ICMJE form. Please note that the list of contributions will publish with the manuscript should it be accepted.

Ghost/Guest Authors

Please note the journal does not allow ghost authorship, based on the definition of ghost authorship as the failure to designate an individual who has made a substantial contribution to the research or writing of a manuscript (JAMA. 2008;299(15):1800-1812). If it comes to light that a substantial contribution has not been disclosed, the journal shall advise the corresponding author and withdraw the submission.

Based on the definition of guest authorship as the designation and acknowledgment of an individual who has contributed significantly but does not meet authorship criteria, any guest authors must (a) provide written permission to the corresponding author which is to be uploaded with the submission and (b) be listed by the corresponding author in the acknowledgments section (after text and before references in manuscript file) for their contribution (e.g., James Smith for statistical analysis). If the guest author is being acknowledged for writing assistance, it should specifically address if the guest author prepared a manuscript draft for the named authors to edit or if the named authors prepared the manuscript and received writing and formatting assistance from the guest author. If not self-employed, the guest author should disclose the name of his/her employer and any funding sources.

Corresponding Author

The corresponding author is the person responsible for a submission and all communication with the journal regarding a submission. The corresponding author must notify the editors and Editorial Office, via the submission form, of the following:
  • Acknowledgment of any guest author, defined as an individual who does not meet authorship criteria but has made a substantial contribution to the research or writing of a manuscript.
  • Confirmation that there are no “ghost authors,” defined as an individual who has made a substantial contribution but does not qualify as an author and has not been disclosed to the editor.
  • Submission of ICMJE conflict of interest and copyright forms from each of the co-authors; conflict of interest forms are required and requisite disclosures should be reported on the manuscript’s cover page.
  • Submission of the Contributorship Form (see Downloadable Forms).
  • Acknowledgment of funding by the US National Institutes of Health (NIH). Articles accepted for publication in Ophthalmology Science from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PubMed Central for public access 12 months after publication. The version of the article provided by Elsevier is the final accepted version after peer-review but before copyediting.
  • Confirmation that Institutional Review Board issues have been addressed in the Methods section of the main manuscript.
  • Confirmation that the authors are aware the journal occasionally, only after acceptance of a submission and on a confidential basis and with no rights prior to embargo date, shares some information with the American Academy of Ophthalmology public relations staff and/or EyeNet staff.
  • .
  • After acceptance for publication, authors may designate more than one person to be contacted by readers.


Study Group/Writing Committee Authorship

If study group/writing committee authorship is used and the corresponding author is the study chair, please state this on the cover page. However, if the corresponding author is not the study chair, please enclose with the submission a statement from the study chair that the group authorship as stated on the cover page and/or members of the responsible writing committee are both correct. The journal promotes transparency of authorship to editors, reviewers, and readers.

Members of the group can be listed in initial group papers in print and in subsequent papers, either by reference to an earlier manuscript, or at times for length and format reasons, in online supplemental material. Members are appropriately acknowledged on the byline “…for the XYZ Study Group” or “… on behalf of the XYZ Group.” If you believe group members are more appropriately acknowledged by including them as authors, each must meet authorship criteria and complete the required ICMJE authorship criteria, copyright assignment, and conflict of interest forms.

With transparency and space limitations in mind, the following are the journal’s policies regarding study group/writing committee authorship:
  1. If an individual is authoring for a group (e.g., a Study Chair) it should be listed as

    Henry A. Fiddle, MD for the Laser ROP Study Group

  2. Small study groups (≤ 10 members) can author as the group or they can list writing committee members names “and the XYZ Study Group” as long as all the members qualify as authors. Otherwise, only those who qualify should be listed and the remainder can be acknowledged.

    Debra L Hanson, MS; Susan Y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, MD; and the Adult and Adolescent Spectrum of HIV Disease Project Group


  3. Large study groups (>10 members) should not author a paper as an entity. In large groups it is not likely that every single member of the group or network contributed as required by the authorship criteria mentioned above. Large study groups should either list the writing committee members as authors followed by “for the XYZ Study Group” or list “Writing committee for the XYZ Study Group*” as the author and the names of the writing committee members will be listed at the end of the article with an asterisk. Regardless, members of the writing committee must qualify as authors and complete the appropriate ICMJE authorship forms.

    Debra L Hanson, MS; Susan Y. Chu, PhD; Karen M. Farizo, MD; John W. Ward, MD for the Adult and Adolescent Spectrum of HIV Disease Project Group OR The Writing Group for the DISC Collaborative Research Group* OR The DISC Collaborative Research Group Writing Committee*
To ensure that writing committee/study group members' contributions are searchable in PubMed, the submission must include a file listing each writing committee/study group member; upload as a Word file, and select “Collaborators” as the file type. When writing committee/study group members are listed as collaborators, PubMed provides an expandable listing under “Collaborators“” as part of the article record. Expandable authorship is appropriate when an author byline includes (1) only a group name or (2) a group name, along with individual authors who are not members of the collaborative group (that is, when author names are listed followed by “, and the XYZ group,” and the participating group member names are NOT included in the byline).

Any digression from these authorship guidelines must be addressed, prior to submission, via email to [email protected]. The Executive Editor and/or Editor-in-Chief will discuss with the corresponding author on a case-by-case basis.

Entering Authors into the Submission System

Enter the title, first and last name, and email addresses for all authors. The number of authors on the submission form must match the list on the title page. Be sure to indicate which author is the corresponding author by checking the appropriate box. All correspondence regarding a submission must come from and will be sent to the corresponding author only. Author order can be changed by dragging the blue handle button up or down next to the author's name. Please do not have staff members list themselves as authors for the purpose of uploading files.

NOTE: Once a manuscript has been submitted, the order of authorship (including adding or removing authors) cannot be changed without a written request to the Editorial Office from the corresponding author. The request must include a statement that all authors agree with the change, signed by all authors. Specifically, if an author is removed, a letter from that author agreeing to their removal is required. If the authors are not able to agree among themselves on authorship changes, please withdraw the paper. The editors and Editorial Office do not arbitrate such debates. Authorship changes cannot be submitted with proof changes. The publisher is not authorized to make such changes.

Cancer Classifications

We encourage authors to use the American Joint Commission on Cancer TNM Classification scheme when describing patients with ophthalmic malignancies. AJCC Cancer Staging Manual. (8th ed. New York, NY: Springer; 2016).

Clinical Trials and Clinical Trial Registration

A clinical trial is defined as any study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. With regards to the reporting of clinical trials, Ophthalmology Science's policies are similar to the policies of The New England Journal of Medicine (NEJM), and The Journal of the American Medical Association (JAMA) which can be viewed at https://jamanetwork.com/journals/jama/pages/instructions-for-authors#SecReportingClinicalTrials.

Please note that these policies include the expectation that all manuscripts reporting clinical trials will include a copy of the original trial protocol, the complete statistical analysis plan and any amendments to protocol and/or plan.

Consistent with these policies, prospective clinical trial registration is required. Please state in the Methods section where the clinical trial registration information is publicly available. Satisfactory public databases include the NIH's http://www.clinicaltrials.gov and the site from the International Standard Randomized Controlled Trials at http://www.controlled-trials.com.

For all manuscripts that report clinical trials, CONSORT guidelines must be followed, including submission of a CONSORT flow diagram and checklist. If a subanalysis of a clinical trial is reported independently and it draws on the same population as the parent trial, the subanalysis can refer to the parent trial report in lieu of including the flow diagram and checklist. If however, the subanalysis reports on a subset of patients, a flow diagram and checklist are recommended.

Our journal supports the CONSORT-AI extension, a reporting guideline for clinical trials evaluating interventions with an AI component. For more information on the CONSORT-AI extension, please refer to:

Liu X, Rivera SC, Moher D, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI Extension. BMJ. 2020;370:m3164; doi:10.1136/bmj.m3164.

Ophthalmology Science endorses the NEJM policies that encourage clarity with regards to the representativeness of the study group (see DOI: 10.1056/NEJMe2114651). Ophthalmology Science encourages the inclusion of a supplementary table that provides disease background with regards to epidemiology and risk, and describes the relevant representativeness of the study group.

In reporting results, Ophthalmology Science strongly recommends that figures include a display of the individual-level outcomes by arm. Presentation methods might include histogram, density plot, scatter plot, or box-and-whiskers plot and should display outcome distribution as well as the overlap between treatment group and controls.

Ophthalmology Science supports the National Institutes of Health Principles and Guidelines for Reporting Preclinical Research. Please refer to the following site for additional information: http://www.nih.gov/about/reporting-preclinical-research.htm

Conflict of Interest (financial disclosure)

Each co-author must complete an ICMJE Conflict of Interest Form and submit it to the corresponding author.

In the interest of transparency, the ICMJE asks to disclose all relationships/activities/interests related to the manuscript content. The ICMJE defines “related” as any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript.

For further information, please refer to: Liesegang TJ, Schachat AP. Enhanced reporting of potential conflicts of interest: rationale and new form. Am J Ophthalmol. 2011:151:391-393.

Liesegang TJ, Bartley GB. Toward transparency of financial disclosure. Ophthalmology. 2014;121:2077-2079.

Liesegang TJ, Bartley GB. Footnotes, acknowledgments, and authorship: toward greater responsibility, accountability, and transparency. Ophthalmology. 2014;121:2297-2298.

All submissions must have the ICMJE Conflict of Interest Form completed and uploaded for each author preferably as part of the initial submission process, but no later than first revision. The form posted on the ICMJE website ((http://www.icmje.org/downloads/coi_disclosure.docx) and enclosed in our guide as a downloadable form includes instructions to help authors provide the correct information.

Every published manuscript will have a statement “All authors have completed and submitted the ICMJE disclosures form” followed by either “None of the authors has any conflicts of interest to disclose.” OR “Authors with financial interests or relationships to disclose are listed prior to the references.” Corresponding authors are asked to confirm or update conflict of interest statements as part of the final steps of manuscript acceptance with the journal office, prior to transmittal to the publisher. For further information, see https://www.elsevier.com/authors/journal-authors/policies-and-ethics

Publication Ethics

Before completing the submission, authors must confirm that their submission conforms with the Elsevier Guidelines for Ethics in Publishing, see https://www.elsevier.com/publishingethics and https://www.elsevier.com/ethicalguidelines.

Copyright

Upon acceptance of an article, authors will need to complete a ‘Journal Publishing Agreement’ (for more information on this and copyright, see https://www.elsevier.com/copyright). The corresponding author will receive an email confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Signed copyright forms state that the undersigned authors either own the copyright or have written permission to use all the material in their article. If authors are submitting any material to which they do not own copyright, they need to secure permission to use the copyrighted materials.

NOTE: Once a manuscript has been accepted, the order of authorship (including adding or removing authors) cannot be changed without a written request to the Editorial Office from the corresponding author. This request must include a statement that all authors agree with the change along with a new copyright form, both signed by all authors. Specifically, if an author is removed, a letter from that author agreeing to their removal is required. The new copyright form must show the title and authors’ names in the order they should appear in print on the top of the form and include original signatures from each author; signature order does not matter. If the original authors are not able to agree among themselves on authorship changes, please withdraw the paper. Authorship changes cannot be submitted with proof changes. The publisher cannot approve such changes and it will delay publication of the manuscript.

Correspondence and Replies

Correspondence allows concise commentary about an article published in the journal within 8 months of its online posting. The text should raise a question for clarification, offer an alternative perspective, or explain a flaw in methodology or a perceived misinterpretation of data. The correspondence should address no more than three points. Correspondence should not be used as an avenue to introduce new material without subjecting it to typical peer review.

Format: Correspondence is limited to 700 words, double-spaced, with no more than 5 references including the article to which the authors are responding. Figures, tables, or graphs are typically not included. The title follows the following format: Re: [insert last name of first author of published article] et al.: [insert title of the published article to which the Correspondence refers.] The correspondence should start with “To the Editor” and the article being commented on should be referenced in the first paragraph and be the first listed reference. Comments such as “… I commend the author for their fine study” or overly critical remarks are neither necessary nor appropriate. Letters should end with the name, degree, and location (city, state or city, country) for each author.

Submission: Completed ICMJE conflict of interest forms from each co-author must be submitted along with the correspondence.

Process: Correspondence is reviewed by the Editor-in-Chief, members of the Editorial Board, and, in rare instances, by outside reviewers. If the editor would like to consider the correspondence further, it is forwarded to the corresponding author of the original article for the opportunity to respond. The corresponding author of the article being discussed will receive an email entitled “Invitation to reply to a letter to the editor regarding your recent Ophthalmology Science article” Authors of the original manuscript are given 10 days to submit a reply. If the invitation is accepted, both the correspondence and reply are edited and published together. If the invitation to reply is declined, the original correspondence may be processed and published by itself.

All correspondence and replies are published online, although the material is listed in the print Table of Contents.

When requested to revise a Correspondence, please submit a point-by-point file to demonstrate how the editor’s questions or recommendations were addressed. The point-by-point template can be accessed at: https://www.elsevier.com/__data/promis_misc/oph-template-form.docx.

Cover Letter

Cover Letters are required for all new or transferred submissions. Please use the cover letter to note if your manuscript was previously submitted to this (please include the manuscript number) or any other journal (see “Rejection of Manuscripts” section of this guide), or to notify the editorial board or Editorial Office of any additional information. If your manuscript is an invited transfer from an Academy companion journal, please include the manuscript number on your cover letter.

Drug and Equipment Names

Drug names

Do not use drug trade names in titles. Please use the generic name in the abstract, as appropriate, but include the trade name once, in parentheses, after the first use of the generic name. Similarly, in the text, use the generic name, but include the trade name once, in parentheses, after the first use of the generic name.

Device/Equipment Names

A device name is permitted in the title, abstract, and text. However, after the device has been identified at first use in the abstract and text, thereafter refer to it generically.

Editorials

Editorials are usually solicited by the Editor-in-Chief, although unsolicited submissions will also be considered. Editorials may address clinical or non-clinical topics in summary form and generally do not exceed 1700 words. If a figure is desirable, please decrease the word count by approximately 200. The ICMJE conflict of interest form should be uploaded with the initial submission and if accepted, the copyright form will be collected during the production stage. Editorials, whether invited or unsolicited, undergo peer review.

English Editing Assistance

The journal office may return a submission and recommend professional editing prior to formal review. Authors who require editing to eliminate grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier’s WebShop https://webshop.elsevier.com/language-editing-services/language-editing/ or visit the customer support site https://service.elsevier.com for more information. However, Ophthalmology Science neither endorses nor recommends any specific individual or service and professional editing does not ensure acceptance of a manuscript.

Figures

Figures (photographs, illustrations, or graphs) will be included in the final PDF but figure file names will not be visible to reviewers. Non-composite figures should be uploaded as individual files and clearly identified. For all figures, the figure number must be entered in the file description field before uploading each figure. To upload figures, go to the “Attach Files” page of the submission form. Click “Browse” to browse your desktop for the files or drag and drop them into the window. Select “Figure” as the File Type. In the “Description” box enter the figure number for each figure file. Please do not upload legends here. Legends for print figures should be included at the end of the Manuscript file. Figures at revision should be uploaded as high resolution .tif or .eps files; one figure per file. Online-only supplemental figures must be PDF files with the legend included in the PDF; one figure per PDF file and uploaded as “Supplemental Figure” files.

Photographs (including those generated electronically from MRI, fluorescein angiography, perimetry, OCT, etc.) must be masked to prevent patient identification. Clinical photographs that permit identification of an individual (those exposing anything more than just the eyes) must be accompanied by a signed statement by the patient or guardian granting permission for publication of the images for educational purposes. All graphics, including composites (such as clinical photographs, fluorescein angiography, CT, MRI, OCT, photomicrographs, etc.) should be submitted at the actual size that they would be presented in the journal, i.e., 100% of their print dimensions to avoid scaling. The width should be no more than 7 inches.

The publisher will not re-draw or rework photographs or other figures. Submit all figures in the order they appear in the legends. If there are 6 or more color pictures, a composite maybe preferred. However, only use composites that do not compromise figure integrity or quality. The completed composite must meet the guidelines for artwork submission. Composites must also be labeled using typed text in the corner of each image. Composites are encouraged for multi-panel figures (e.g., Fig 1A, 1B, 1C, 1D, 1E). Please see this chart for additional details: https://www.elsevier.com/__data/promis_misc/OPHTHAFigurechartupdated.pdf and Elsevier's Artwork and Media Instructions https://www.elsevier.com/authors/author-schemas/artwork-and-media-instructions.

General
  • Physical dimensions of artwork must fit dimensions of the pages within the journal (i.e., width no more than 7 inches).
  • Be consistent in font type and size used in the artwork (8-point Helvetica).
  • Artwork must use recommended naming conventions. Some examples include fig1.tif (figure 1 in TIFF format). Ensure the file extension is present to allow format identification.


Style Points

Please adhere to the following journal-specific style points when creating figures:
  • Remove commas from thousands
  • Change commas to decimals in numbers on axis
  • Add part labels to figure panels
  • Use letters for footnotes not symbols
  • Add spacing around mathematical equations in figures/graphs
  • Use title case in the X/Y axis labels (i.e., capitalize the first word, last word, and all major words in between)


Financial Support

Please disclose all funding sources, public and private. On the title page please state “Financial Support: None” or provide the agency name and city, company name and city, fellowship name, and grant number. If there is financial support, please provide also one of the two following statements, “The sponsor or funding organization had no role in the design or conduct of this research.” OR “The sponsor or funding organization participated in (list those that are appropriate, e.g., the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, review or approval) of the manuscript.”

Institutional Review Board

If the study involved human subjects, human-derived materials, or human medical records, please include one of the two following statements in the Methods section: “Institutional Review Board (IRB)/Ethics Committee approval was obtained” OR “IRB/Ethics Committee ruled that approval was not required for this study.” For Report submissions only: If institution's IRB does not require approval for case reports, provide an exemption letter or public URL that reiterates the policy that approval is not needed.

Legends

Legends for photographs, illustration, graphs, etc. should be written to be understandable on their own, without reference to the article’s text. Figures must be numbered consecutively as they appear in the text. Histological figures, stains, and magnifications should be noted in the legends. Any figure that has been published elsewhere should have an acknowledgment to the original source; a copy of the release to publish the figure, signed by the copyright holder, must also be submitted. Legends must identify all symbols, abbreviations, acronyms, or letters that appear on the prints. Table legends should be within the table. All abbreviations in each table must be defined even when repetitive to other tables.

Manuscript Text Format

Double-space the entire manuscript after the title page and add continuous line numbering to the manuscript file. The average published manuscript in Ophthalmology Science, including references, is 6 printed pages or less. This corresponds, depending on font size and printing, to 16-20 pages of double-spaced draft.

1. Title Page
The title page should include the following information.
  • a) Title: The title should be meaningful and brief (no longer than 135 characters); abbreviations should not be used. Please ensure the manuscript title on the cover page matches the title entered into the submission system.
  • b) Authors: Provide first name, middle initial, last name, and no more than two advanced degrees. The journal does not print society affiliations. Indicate each author's affiliation during the course of the study in footnotes on the title page using superscript numbers, not symbols (e.g., John Smith1). Specifically identify the corresponding author. Please carefully review the Authorship section of this guide, which addresses authorship criteria, group/writing committee authorship, ghost authors, guest authors, corresponding authors, and related responsibilities. Verify numbers of authors when entering author names into the system.
  • c) Meeting Presentation: If the material is under consideration for presentation or has been previously presented, supply the name, place, and date of the meeting. (e.g., the American Academy of Ophthalmology Annual Meeting, 20XX). This is especially important for AAO Meeting papers as the journal has the right of first refusal for these manuscripts.
  • d) Financial Support: Identify all sources, public, and private. On the title page please state “Financial Support: None” or provide the agency name and city, company name and city, fellowship name, and grant number. If there is financial support, please provide also one of the two following statements, “The sponsor or funding organization had no role in the design or conduct of this research.” OR “The sponsor or funding organization participated in (list those that are appropriate, e.g., the design of the study, conducting the study, data collection, data management, data analysis, interpretation of the data, preparation, review or approval of) the manuscript.”
  • e) Conflict of Interest: A blanket statement that “no conflicting relationship exists for any author” is requested on the title page, if appropriate. Otherwise, the corresponding author should summarize the disclosures sent by each author and upload the ICMJE COI form of each author.
  • f) Running head: The running head, also known as the short title, which appears on the top of each right-hand published page of the manuscript, should be a maximum of 60 characters.
  • g) Address for reprints


2. Abstract – see separate “Abstract” section



3. Text
  • a. Introduction: Without a heading, the two- to three-paragraph introduction should explain why the study was done and what hypothesis is being tested. The introduction should refer only to the most pertinent past publications and should not be an extensive review of the literature.
  • b. Methods, Intervention, or Testing: This section should be written with sufficient detail to permit others to replicate the work. Also required are the following, as appropriate within the methods section:
    FOR HUMAN SUBJECTS:
    • Informed Consent - Manuscripts reporting the results of experimental investigation on human subjects must include a statement that informed consent was obtained (see Ophthalmology 2003;110:1074-5).
    • IRB/Ethics Committee - Human subjects/materials/medical records - If the study involved human subjects, human-derived materials or human medical records, please include one of the following statements in the Methods section: "Institutional Review Board (IRB)/Ethics Committee approval was obtained" OR "IRB/Ethics Committee ruled that approval was not required for this study."
    • Declaration of Helsinki - A statement is required that the described research adhered to the tenets of the Declaration of Helsinki.
    • Clinical Trial Registration - A statement in the Methods confirming where the clinical trial is registered and publicly available. (See Clinical Trial Registration for more detailed information.)
    • Authors are encouraged to use the American Joint Commission on Cancer TNM Classification scheme when describing patients with ophthalmic malignancies (AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2016).
    FOR ANIMAL SUBJECTS:
    • If animals were used in a study, the notice of approval by the appropriate Institutional Animal Care and Use Committee should be included in the Methods section of the manuscript.
  • c. Results: Results should be concise. Information presented in tables should not be repeated in the text.
  • d. Discussion: The discussion should be restricted to interpretation and application of the study’s notable findings. Discussion is the final section of a manuscript. Please do not insert a conclusion section; only the abstract has a conclusion section.


Online Supplemental Materials

Ophthalmology Science is entirely published online. The main manuscript, tables, and figures are published online. Authors are encouraged to provide supplemental materials including tables, charts, figures, etc. that would further enhance the published article.

The availability of additional information will be noted in the Table of Contents by a tablet or video icon. The materials are archived with the online version of the article on the journal's website https://www.ophthalmologyscience.org and accessible through Medline and other online databases. In the manuscript, on the cover page, and in the appropriate corresponding section of text, there will be a notation that indicates “Supplemental material available at https://www.ophthalmologyscience.org.”

When opting for supplemental material, add a reference to it in parentheses after the mention of information to appear as supplemental material: For example, “…as shown in Table N (available at https://www.ophthalmologyscience.org).” Supplemental tables or figures should be numbered consecutively as they appear in the text, in the same sequence as figures or tables. Also, add a statement to the title page that should read similar to “This article contains supplemental material. The following should appear as supplemental material: Figures X, Y, Z and Table N.” All supplemental files must be submitted as PDF files. One table, figure, or appendix per PDF file. Please note that these files will not be copyedited or composed and will be posted online as they appear submitted.

All supplemental materials must follow the same criteria as if they were to appear in the main publication online. For example, tables must be able to stand alone with all abbreviations, references, etc. identified. Table legends would include definitions for the abbreviations, if any. Supplemental Figures must include the legend with the image in the PDF file.

Permission to Use Copyrighted Materials

Permission requests should be submitted via the online form at https://www.elsevier.com/about/policies/copyright/permissions as it ensures that Global Permissions receives the most complete information regarding your request. Requests may also be sent to Elsevier Health Sciences Rights Department, Global Rights Department, Oxford, United Kingdom; phone: 44-(0)1865-843830; fax: 44-(0)1865-853333. Email: [email protected].

You may contact the Permissions Helpdesk ([email protected]) with any questions prior to submitting your request. Authorization to photocopy items for internal or personal use or the internal or personal use of specific clients is granted by the American Academy of Ophthalmology, Inc. [Applies to libraries and others registered with the Copyright Clearance Center (CCC) transactional reporting service provided that the base fee of $20 is paid directly to CCC, 222 Rosewood Drive, Danvers, MA. 01923.] All other copyright inquiries should be addressed as shown above.

Permission to use materials to which others hold copyright in a submission to Ophthalmology Science.

The copyright form states that the author either owns the copyright or has written permission to use all the material in a submission. Examples include a clinical image/chart that was published in another journal or book, or a photograph of an ophthalmic device obtained from a pharmaceutical company. In most cases, permission can be obtained by e-mailing the publisher or company and explaining specifically what the author wishes to use, where (online version of Ophthalmology Science), and why (in an article entitled XXXXX). Most copyright holders will reply with a “permission granted” letter which should be uploaded with the submission. Please allow ample time (typically 3-6 weeks) to receive permissions.

Précis

All full-length manuscripts must include a précis of 35 words or fewer summarizing the main finding/outcome of the study. The précis should be written in complete, unbulleted sentences and not merely duplicate the abstract conclusion. If the paper is published, the précis will appear under the title in the Table of Contents. The précis is submitted as a separate file and should not be included in the manuscript file. Please refrain from using abbreviations/acronyms in the précis.

Preprint Server

For work submitted to a preprint server, it is the corresponding author's responsibility to promptly update the preprint server entry to indicate when a paper has been accepted and is currently in press; the author must add proper citation of the online version to the preprint server entry to point users to the peer-reviewed, accepted version of the article.

Prior and Repetitive Publication; Plagiarism

The journal will not consider manuscripts that have appeared in other journals, in part or in whole, except in special circumstances approved by the Editor-in-Chief. Likewise, updates of previously published studies that add minimal new information to an existing publication will not be considered. Overlap between patient groups described in serial manuscripts must be acknowledged, and references to previous publications that include the same patients must be provided. Authors uncertain as to whether specific data might be considered prior or repetitive publication should alert the Editor-in-Chief on their cover letter and provide copies of the publications in question.

To decrease the risk of unintentional plagiarism, and potential copyright violations, please consider analyzing your manuscript with plagiarism detection software prior to submission. Several programs are commercially available. The publisher uses iThenticate to verify the originality of written work when a manuscript is received. If duplicative text from published sources, whether from the author(s) previous work or not, is identified without proper citation, the manuscript cannot be considered for peer review and will be returned to the authors. For additional information, please consult: Bartley GB, Albert DM, Liesegang TJ. Choosing Our Words Carefully: Plagiarism in the Internet Age. Ophthalmology. 2014;121:807-808. Available at https://www.aaojournal.org/article/S0161-6420%2813%2901249-9/fulltext.

Precedence

Ophthalmology Science strongly discourages claims of precedence or size. Authors who nevertheless claim precedence for an idea, observation, or therapy should describe the literature search methodology used to support their assertion.

Reference Format

Indicate references by (consecutive) superscript Arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. For further detail and examples, please refer to the AMA Manual of Style, A Guide for Authors and Editors, 11th Edition, ISBN 978-0190246556.

Number references in the order in which they appear in the text.

Most manuscripts in Ophthalmology Science are neither intended to be review articles nor require encyclopedic referencing. Twenty or 30 references suffice for most manuscripts and nearly all can be presented with less than 40. This limitation does not apply to Systematic Reviews or Meta-analyses.



Examples:

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun. 2010;163:51-59.

Reference to a book:

2. Strunk W Jr, White EB. The Elements of Style. 4th ed. New York, NY: Longman; 2000.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, eds. Introduction to the Electronic Age. New York, NY: E-Publishing Inc; 2009:281-304.

Reference to a website:

4. Cancer Research UK. Cancer statistics reports for the UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer-heading-Zero; 2017 Accessed March 3, 2013.

Reference to dataset:

5. Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://data.mendeley.com/datasets/xwj98nb39r/1.

Reports

Reports are typically submitted after invitation from the Editorial Board. Specifically, some full-length manuscripts contain noteworthy information that can be presented in a more concise format. The Editorial Board may invite the authors to abridge their work, taking into consideration suggestions for revision in the initial reviews, and resubmit the paper as a Report.

Ophthalmology Science has the right of first refusal to any manuscript or Report derived from a presentation at the American Academy of Ophthalmology Annual Meeting. An invitation is not required for material that has been submitted to or accepted for presentation at the Academy Annual Meeting (see the AAO Meeting Papers and Poster section).

The submission should be double-spaced and include a title of not more than 80 characters (spaces included). Reports may not exceed 1000 words or include more than 7 references, and may feature one figure, graph, chart, or concise table in the main manuscript. Three additional items can be included as supplemental material. Please insert “(available at https://www.ophthalmologyscience.org)” at relevant point(s) in your manuscript. Please note that supplemental material must conform to the same requirements regarding legends, abbreviations, etc. as for the main manuscript. A 35-word unstructured abstract is required for editors'/reviewers' view only and will not publish with the report. Please submit a 35-word unstructured abstract on the online submission form field labelled “abstract.”

The text should be in narrative rather than a structured format. When uploading Reports, please select “Report-Invited” article type, and include the manuscript number of the original submission on the cover letter. Please include a point-by-point response to the original reviewer(s)'' questions and suggestions. Please note that an acknowledgment section is reserved for grants and funding only. Please consider the following resources that may help improve reporting of case series submissions:
  1. Jabs DA. Improving the Reporting of Clinical Case Series. Am J Ophthalmol. 2005;139(1):7-10.
  2. Kempen J. Appropriate Use and Reporting of Uncontrolled Case Series in the Medical Literature. Am J Ophthalmol. 2011;151(5):900-905.
  3. Di Loreto DA, Bressler NM, Bressler SB, Schachat AP. Use of Best and Final Visual Acuity Outcomes in Ophthalmological Research. Arch Ophthalmol. 2003;121(11):1586-1590. doi:10.1001/archopht.121.11.1586


Review Articles

Systematic Reviews and Meta-analysis

Systematic reviews seek to collect, synthesize, and critically assess all evidence that fits pre-specified criteria to answer a clinical question pertaining to the cause, diagnosis, prognosis, prevention, or therapy for a condition. A systematic review may contain a meta-analysis, which uses statistical methods to combine results from similar but independent studies.

It is possible to conduct a systematic review and meta-analysis of the evidence supporting any type of research question, whether the question is about intervention effectiveness or harm, etiology, prognosis, diagnostic accuracy, toxicity, incidence, or prevalence. Where intervention effectiveness questions are typically addressed by randomized controlled trials, most other questions are addressed using observational studies. Systematic reviews may also be conducted for human or animal studies.

Authors should state whether there was an a priori protocol for the review, and ideally reference a published protocol or provide a copy of the protocol as Supplementary Materials. At a minimum, the systematic review should have been prospectively registered (e.g., in PROSPERO: https://www.crd.york.ac.uk/PROSPERO/). The registration number should be included in both the abstract and text.

Key features of a systematic review include:

  • a clearly stated set of objectives with pre-defined eligibility criteria for studies;
  • an explicit, reproducible methodology;
  • systematic literature searches that attempt to identify all relevant studies meeting the eligibility criteria;
  • an assessment of the internal validity of included studies, for example by assessing risk of bias using a validated tool (e.g., Cochrane risk of bias tool for randomized controlled trials, AMSTAR or AMSTAR-2 for systematic reviews); and
  • systematic presentation, and synthesis of the characteristics and findings of the included studies (see Higgins JPT, Thomas J, Chandler J, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 [updated July 2010]. Cochrane, 2019. Available at: www.training.cochrane.org/handbook).


Further details regarding current best practices for the conduct and reporting of systematic reviews can be found here, and the elements described should be explicitly addressed within the submission. For standards and classic references in conducting systematic reviews and meta-analyses, please refer to:

  • Institute of Medicine. Finding what works in health care: standards for systematic reviews.2011.
  • Higgins J, Lasserson T, Chandler J, et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Version March 2020. Available at: https://community.cochrane.org/mecir-manual.
  • Higgins JPT, Thomas J, Chandler J, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.0 [updated July 2010]. Cochrane, 2019. Available at: www.training.cochrane.org/handbook.
  • Cochrane Handbook for Diagnostic Test Accuracy Reviews [In progress]. Available at: https://methods.cochrane.org/sdt/handbook-dta-reviews
  • Little J, Higgins JPT (eds). The HuGENE® HuGE Review Handbook, version 1.0. Guidelines for systematic review and meta-analysis of gene disease association studies (see also Systematic Reviews of Genetic Association Studies, PLoS Medicine 2009;6(3):e1000028)
  • Systematic Reviews. CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, 2009. DOI: https://doi.org/10.1016/S1473-3099(10)70065-7


A complete list of guidelines for reporting systematic reviews and meta-analyses can be found at the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network's website (see https://www.equator-network.org/reporting-guidelines/). We strongly recommend you visit the EQUATOR's website for reporting guidelines for systematic reviews and meta-analyses of other study designs (e.g., individual participant data, health equity, genetic association studies).

For reporting systematic reviews and meta-analyses, if you are submitting a report of:

  • A systematic review and/or meta-analysis of randomized controlled trials, please follow the appropriate PRISMA guidelines for reporting (see http://www.prisma-statement.org/);
  • A systematic review and/or meta-analysis of observational studies, please follow the MOOSE guidelines for reporting.


The appropriate reporting checklist and flow diagram should be completed and included with the submission; this may be as Supplementary Material.

Title Page:

The title should clearly describe the research question and identify the report as a systematic review, meta-analysis, or both in the subtitle. (Example: Anti-vascular endothelial growth factor for neovascular age-related macular degeneration – A systematic review and meta-analysis.)

Précis:

The précis should indicate a new insight the article offers or a principal controversy that is addressed.

Structured Abstracts:

Abstracts for systematic reviews and meta-analyses must be limited to 350 words and include five sections following the PRISMA guidelines:
  • Topic: provide an explicit statement of the specific clinical question being addressed with reference to a brief description of the participants, interventions (or exposures), comparators, and outcomes examined.
  • Clinical relevance: characterize the magnitude and importance of the condition; when relevant, define the current standard of care.
  • Methods: describe the key eligibility criteria for including studies in the systematic review, key databases searched and search dates, methods of assessing the risk of bias in the individual studies.
  • Results: summarize the number and type of included studies and participants, and relevant characteristics of studies; describe the results of main outcomes (benefits and harms), preferably indicating the number of studies and participants for each. If a meta-analysis was done, include summary measures and confidence intervals; report the direction of the effect or association (i.e., which group is favored) and size of the effect using language meaningful to clinicians and patients.
  • Conclusion: summarize the strengths and limitations of the evidence, your general interpretation of the results, and important implications.


At a minimum, the systematic review should have been prospectively registered (e.g., in PROSPERO: https://www.crd.york.ac.uk/PROSPERO/). The registration number should be included in both the Abstract and Text. Note that the abstract content and conclusions should agree with what is in the manuscript text.



Manuscript text

The text should use standard journal formatting and be divided into four distinct sections. The brief descriptions below are gathered from the PRISMA Checklist: http://prisma-statement.org/documents/PRISMA_2020_checklist.docx and PRISMA flow diagrams: http://prisma-statement.org/PRISMAStatement/FlowDiagram, the MOOSE guidelines, and the Standards for the Reporting of Cochrane Intervention Reviews. The text should report institutional review board approval or exemption, financial disclosures and potential conflicts of interest of the authors, and funding sources of the review.



1. Introduction (unlabeled) should provide a concise description of the condition or clinical problem addressed by the review question, provide perspectives on the importance of its management to patient well-being and quality of life, and why it is important to do the review. Always end the introduction with a clear and concise statement of the study’s main objectives or hypotheses.

2. Methods: The methods section should include the following subheadings:
  • Eligibility criteria for considering studies for this review: state eligibility criteria for participants, interventions (or exposures) and comparators, and eligible study design(s) if applicable. Define primary and secondary outcomes of the review and state whether an article had to report measurement of at least one of the outcomes to be eligible. If so, provide rationale.
  • Search methods for identifying studies: list all information sources searched, including databases, trial registries, websites, difficult-to-access literature (e.g., grey literature, conference proceedings), reference lists of included studies, and whether individuals or organizations were contacted. For all searches, provide the date of the last search and whether there was any time period or language restriction. Present the exact full search strategy (or strategies) used for at least one database in an Appendix with sufficient detail to permit replication. Report which software was used to manage the records identified and eligibility status.
  • Study selection: describe the process for selecting studies, how many people were involved at each step of the review, whether any steps were done by more than one person, and if so whether they worked independently and how different opinions were resolved.
  • Data collection and risk of bias assessment: List and define data items extracted from the reports of included studies. Describe methods used for assessing risk of bias of included studies (risk of bias is a formal assessment of what is often considered study “quality”), and how this information was used in any data synthesis. Describe the process for data extraction and risk of bias assessment, how many people were involved at each step, whether any steps were done by more than one person, and if so whether they worked independently and how different opinions were resolved. Report the software used for data collection and management.
  • Data synthesis and analysis: state the methods for combining results across studies, which include qualitative synthesis and quantitative synthesis (i.e., meta-analysis). State the summary measures used to quantify the treatment effect or association such as risk ratio, odds ratio, and difference in means. Describe methods for assessing clinical, methodological, and statistical heterogeneity (e.g., I2 statistic, tau-squared, statistical test). Describe methods for additional analyses such as meta-regression, subgroup analysis, and sensitivity analysis, if done, indicate which were pre-specified. State the statistical software used for analysis. Indicate whether a systematic review protocol exists, if so, where and how it can be accessed; and if available, provide systematic review registration information including registration number.




3. Results: Provide numbers of studies retrieved, screened, assessed in full for eligibility, included in the review, and included in the meta-analysis, with reasons for exclusion at each stage, ideally with a flow diagram. Present characteristics of included studies including information on the study design, participants, interventions (or exposures) and comparators, outcomes, and source of funding, ideally in a table. Present domain-based risk of bias assessment of each study, ideally in a table or a figure. Composite quality scores and scales are discouraged. For all outcomes considered, irrespective of the direction or strength of the results, present, (1) simple summary data for each group, and (2) estimates of treatment effect (or association) between groups with a measure of statistical uncertainty (e.g., confidence intervals). If meta-analysis was done, report meta-analytical results ideally with a forest plot, number of studies and participants for each meta-analysis, as well as measures of statistical heterogeneity. Present results of any additional analyses (such as meta-regression, subgroup analysis, and sensitivity analysis) if done. Provide a thoughtful qualitative synthesis by analyzing the nature, strengths, and weaknesses of the evidence, and developing a deeper understanding of how an intervention might work (or not), or whether a true association exists, for whom and under what circumstances.

4.Discussion: Summarizes the main findings including the strength of evidence for each main outcome. Provide a general interpretation of the evidence considering their relevance to key stakeholders, including patients, healthcare providers, researchers, payers, and policy makers. A Summary of Findings or GRADE table is optional. Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified studies, reporting biases). Provide a general interpretation of the results in the context of other evidence, and implications for practice and future research.

In the cover letter to the Editor, please state explicitly (1) whether reporting guidelines have been followed, if so, which reporting guidelines; (2) whether the exact full search strategy (or strategies) used for at least one database was presented in an Appendix with sufficient detail to permit replication. Failure to follow the reporting guidelines or upload the search strategy may result in delay in review or rejection of the manuscript. Please submit a PRISMA worksheet and diagram as separate files.

Checklist: http://prisma-statement.org/documents/PRISMA_2020_checklist.docx

Diagrams: http://prisma-statement.org/PRISMAStatement/FlowDiagram

Translational Science Reviews

Translational Science Reviews aim to provide authoritative summaries of state-of-the-art research that bridges the gap between basic and clinical science and which may have broad clinical impact within a few years. For example, in the years prior to the FDA approval of anti-VEGF drugs to treat neovascular age-related macular degeneration, an article in this section might have summarized the relevant basic research that supported Phase 1 human studies for anti-VEGF drugs that are now widely used. Manuscripts should be broadly accessible as the intended audience includes ophthalmologists whose primary focus is usually clinical practice. Please avoid jargon and do not assume that laboratory techniques will be understood by all readers. Translational Science Reviews are usually solicited by the by the editorial board for this section. Suggestions for topics are welcome, however, and can be directed to the Editorial Office (send suggestions to ([email protected]) and add “Ophthalmology Science TSR” in the subject line).

Statistics

Ophthalmology Science follows The New England Journal Medicine's guidelines for the design and reporting of research studies, for both observational studies and clinical trials (see https://www.nejm.org/author-center/new-manuscripts “Statistical Reporting Guidelines”). These include a clear description of sample size and power calculations, appropriate management of missing data, appropriate adjustment for multiple comparisons, significance tests accompanied by confidence intervals, and care to avoid over precision in the reporting of P values. For clinical trials, Ophthalmology Science strongly encourages submission of the original statistical analysis plan along with any subsequent amendments. The analysis should reflect the primary and secondary outcomes as reported in the initial protocol, with clear justification for any deviation.

Study Design

Authors are asked to describe the design of their study as part of the structured abstract. Doing so serves several purposes. It encourages authors to give careful thought to what they have actually done, it provides a useful shortcut for editors and reviewers to categorize the submission, and it gives the reader a useful descriptor of the type of study that was performed.

The CONSORT Worksheet http://www.consort-statement.org/Media/Default/Downloads/CONSORT%202010%20Checklist.doc for randomized controlled trials has been required since 1996 and is available online. The following chart (https://www.elsevier.com/__data/promis_misc/OPHTHA_STUDY_DESIGN.docx) provides basic information regarding study designs.

Tables

Please give careful consideration to the number of tables submitted. The information should not be extensively iterated in the text. Place the information in the text or in a table but not both.

Each table must be titled and numbered consecutively as mentioned in the text. Each column must have a heading. Terminology used within tables should be able to stand independently, without the requirement of explanation from the text. Use abbreviations and acronyms only if imperative for reasonable table formatting. All abbreviations and acronyms must be explained in the table legend. References for tables should be included in the main reference list. If unpublished data or abstract need to be referenced in a table, please place it as a footnote.

Tables for publication must be uploaded as individual Word documents, one table per file. If a table is longer than one page in Microsoft Word, it may be too large and would work better as a Supplemental Table. Supplemental Tables must be uploaded as PDF files, one table per PDF file.

Video Clips

If submitting a video, add a reference to it in parentheses at an appropriate place within the text of the manuscript. Also, add a statement to the title page that should read similar to “This article contains video(s). The following videos should appear: Clip 1, Clip 2, and Clip 3.” The materials will be archived on the publisher’s website https://www.ophthalmologyscience.org and accessible through Medline and other online databases.

We do not have video editing software, but a website with useful tips on reducing file size can be found at https://www.deskshare.com/Resources/articles/dmc_ReduceFileSize.aspx

  1. Maximum: 8 minutes total. We recommend several smaller clips that do not exceed 8 minutes.
  2. Size: recommended size 10-50 MB, and the maximum size is 100 MB.
  3. File extension types: .MPG (MPEG-1 or 2), .AVI, .MOV
  4. Upload a still image of each video clip.
  5. Audio commentary to describe the video is highly recommended. Please do not use background music.
  6. Within the submission, there must be a brief legend describing contents of the video and indicates the viewing order.
  7. Video files should be loaded with the submission into the electronic submission system. File names should correspond to video legends.
  8. On the title page include “This manuscript contains [insert number of video clips].
  9. Upload with submission using the “multimedia” file type.


REVIEW PROCESS

Review and Publication Process

It is the corresponding author’s responsibility to check periodically the status of his/her manuscript. An e-mail with a decision will be sent with instructions to the corresponding author to go to the online submission site if a revision is warranted.

Each manuscript submission will be acknowledged in the order received in the Editorial Office. The acknowledgment letter will note the number assigned to the manuscript. All subsequent inquiries about the manuscript must indicate the manuscript number. Usually, Editorial Board members and two or more reviewers will participate in the review of a manuscript. The journal does not reveal the identity of its reviewers but does provide pertinent comments to the corresponding author. Re-review may be required after revision if, in the judgment of the Editor-in-Chief, sufficient modification of the manuscript or data justifies another review cycle or if one (or more) of the reviewers requested to see the revision. A point-by-point response is required to the reviewers’ comments. Authors should upload two versions of the revised manuscript – one with “track changes” to show where revisions have been made and a “clean” copy. Revised manuscripts are due within 60 days. The Editor-in-Chief has final authority on all editorial decisions unless the editor has been recused, e.g., if the editor is an author, in which case the review process is overseen and the decision made by a designated editorial board member.

Revision Submission

If invited to revise a manuscript, the corresponding author will receive an e-mail that contains the revise decision as well as the reviewers’ and/or editors’ comments. Log on as an author to https://www.editorialmanager.com/XOPS/default.aspx with your username and password. The manuscript will be in the author menu under “Submissions Needing Revision.”

Review the editor/revision comments and, as appropriate, make changes to files based on these comments as well as the Editorial Office comments. Save two versions of the manuscript file – one showing “track changes” and the other a clean copy with all changes accepted. When all files are revised, go to https://www.editorialmanager.com/XOPS/default.aspx. Under “Submissions Needing Revision” select “Revise Submission” to start the revision submission. Revised manuscripts are due within 60 days.

Instructions are provided on how to upload revised files and replace old ones in the “Attach Files” section. The following File Types are required to submit a revised article:
  • Manuscript File (the clean revised version)
  • Revised Manuscript File with Track Changes
  • Précis
  • Author Contributorship Form
  • ICMJE COI Form (one per author)
  • Cover Letter
  • Response to Reviewers (Point-by-Point response)


A final opportunity is provided to review the completed revised version before clicking the final button “Complete Submission.” Please read and acknowledge the Ethics in Publishing statement before final submission.

If you elect to withdraw your paper rather than submit a revision, please log on to the system and select “Decline to Revise.”

PLEASE REMEMBER:
  1. Point-by-point response: Please include a point-by-point response to each of the comments from the reviewer(s), editor(s), and/or Editorial Office. One technique that has proved useful both for authors and the Editorial Office is to create a 3-columned table, in a Word file, to summarize your revisions. (See template https://www.elsevier.com/__data/promis_misc/oph-template-form.docx and samplehttps://www.elsevier.com/__data/promis_misc/oph-sample-form.docx.) In the first column, list the reviewer's suggestion, question, or comment. In the second column, outline your response. If you disagree with the reviewer, please explain your reasoning. In the third column, specify where in the manuscript you have made any changes. Adding line numbers to the manuscript file and referring to specific line numbers will be useful in determining which parts of the manuscript changed. Please ensure that revisions in the text are also changed in the abstract, if applicable, and any relevant tables and relevant tables and/or figures.
  2. References: At first revision, please review the reference format style guide and ensure that references are in the correct format.
    • To expedite processing of a revised manuscript, please provide a photocopy of the title page (including journal name, volume number, year, page numbers) of any work cited that was published prior to 1970 in the United States. This information can be submitted as “related file.”
  3. Figures: Please note any changes to figures in the point-by-point response.
    • If applicable, the revision decision letter will provide instructions on how to prepare figures to meet specific artwork guidelines for the publisher. If you cannot meet these guidelines, contact the Editorial Office before submitting your revisions.
    • Please insert into the text at first mention of the supplemental figures “(available at www.aaojournal.org)” as well as specify on the cover page which figures are to be supplemental materials.
  4. Authors: Please ensure the manuscript title on the cover page matches the title entered into the submission system. Any changes to authors require written explanation, as detailed above under “Authorship.”
  5. File submission: Please upload two versions of your revised manuscript -- one showing “track changes” and one that is “clean.” Do not submit more than one version of any other file type unless specifically requested by the Editorial Office. Each file, revised or not, should be the current version of the submission. If not done with the initial submission, ICMJE conflict of interest forms from all authors and the Contributorship Form are required at revision.


Rejection of Manuscripts

By Other Journals

Rejection by another journal does not compromise consideration by Ophthalmology Science. Authors are required to inform the Editor-in-Chief of rejection by another journal on the cover letter and include copies of the previous review and the authors’ responses. Please use the point-by-point response template: https://www.elsevier.com/__data/promis_misc/oph-template-form.docx

Appeals Regarding Manuscripts Rejected by Ophthalmology Science

Ophthalmology Science is able to accept a selected number of submissions received. Therefore, many good manuscripts are declined, oftentimes despite favorable peer reviews. If your paper is rejected but the reviews are accurate, please do not appeal the decision or request additional reviews. Doing so distracts the journal's editors/reviewers from evaluating submissions and editorial staff from processing other manuscripts and is unfair to the authors of those papers. If, however, the reviewer or editor assessments are reconsidered, the Editor-in-Chief will entertain an appeal and reopen the manuscript's file.


Any appeal must be made by the corresponding author to the Editorial Office by email prior to resubmitting the manuscript. Please do not resubmit a revised version of a rejected manuscript without an appeal to the Editorial Office. Please do not resubmit until your original manuscript is released back to you. By waiting for the manuscript release, it ensures that your paper is processed under the same manuscript number, keeping the manuscript history intact. All resubmissions must be accompanied by an explanatory cover letter.

Occasionally, a manuscript is rejected but the Editorial Board offers the option to resubmit a revised, abridged version as a Report. Please see the Report section for details.

Peer Review

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

Reference Management Software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link: http://open.mendeley.com/use-citation-style/ophthalmology When preparing your manuscript, you will be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Research Data and Data Sharing

Ophthalmology Science encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data Linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with several repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Data Sharing

To promote transparency and opportunities for further research, authors of work published in Ophthalmology Science are encouraged to provide access to relevant datasets in compliance with contemporary reporting standards. Authors may use domain-specific public archives (for example, ClinicalTrials.gov, GenBank, Protein Data Bank), or generic databases (for example, Dataverse, Dryad, Mendeley, or the Open Science Framework, or an institutional repository).

For additional information, please consult:

Taichman DB, Backus J, Baethge C, et al. Sharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors. JAMA. 2016;315(5):467-468.




Proofs

If the submission is accepted, the corresponding author will receive typeset page proofs online. Each corresponding author is expected to proofread all pages carefully and answer all queries posed by the copy editor. Page proofs should be reviewed by more than one person to enhance accuracy. All page proofs must be returned to the publisher within 72 hours of receipt to avoid delay in publication. The publisher does not send reminders; responding to the publisher with responses to author queries and requested changes is the corresponding author’s responsibility. The journal reserves final editorial approval for style, format, and grammar.

Reprints

A reprint order form will either be e-mailed or accompany your copyedited manuscript and page proofs. You must return this form to the publisher with your corrected page proofs, whether or not you order reprints. The cost of reprints increases significantly if they are ordered after the initial print run. Reprints, except special orders of 100 or more, are available only for authors.

Cover Figures

Ophthalmology Science publishes photographs and images on the online issue cover of the journal.

We will consider submissions for cover figures accompanied by a descriptive caption from professional ophthalmic photographers and clinicians. Images should be visually striking, technically excellent, and of appropriate size for the cover format. Cover submissions are submitted and evaluated once a year (typically after the American Academy of Ophthalmology's Annual Meeting). Please submit your cover image(s) for consideration between October 1-31, 2022. If we receive a cover submission before this date, it will be returned to the submitter. For questions, contact the editorial office at [email protected].

Please use the subject header “Cover Image for Ophthalmology Science” so that the e-mail is appropriately flagged. Send the Editorial Office a JPG version of the image along with a photograph title, photographer and institutional affiliation, and equipment used to capture the image. If the photograph is appropriate, the Editorial Office will work with the submitter to generate appropriate file(s) for publication (see technical considerations below).

If an image is selected for use as a potential cover image, Ophthalmology Science will need a completed copyright transfer form (see Downloadable Forms). Once the form is received, the Editorial Office will assign the image for a future issue. Please be aware that it may be several months before it appears in print.

Technical Considerations

The journal cover requires high-resolution files to achieve the best quality. Should an image be chosen for the cover, the file(s) should be available as minimally compressed JPG or ideally uncompressed (e.g., TIF or PSD) high-resolution files of at least 8"x8" at 300 dpi. Screen grabs from video (even high-definition video) do not upscale adequately for print and can appear blurred; similarly, output from most diagnostic instruments do not upscale well and can look pixelated.

Please do not perform any post-processing of the digital image other than light dusting and spot removal. sRGB color space is fine; do not convert to CMYK as this will be done by the publisher during pre-press processing. The high-resolution files for final publication are usually too big to send by e-mail. A web-based large file transfer service (e.g., https://www.hightail.com/) can be used; please contact the Editorial Office ([email protected]) if you need assistance with transmitting large files.

Copyright Considerations

Copyright for images must be transferred to the American Academy of Ophthalmology. The copyright transfer form must be signed by all listed authors. Please note that if the image has already appeared as part of an article in another journal or in a textbook, the author or photographer probably does not have the right to transfer the copyright to the Academy. Similarly, if the image has appeared as part of a photography contest (and especially if it won a prize), the conditions of contest participation should be clarified. The copyright transfer form should be submitted to the Editorial Office at [email protected].

In Press/Online Release

Availability of Accepted Articles

This journal makes articles available online as soon as possible after acceptance. This concerns the accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset, or proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable by title, author name(s), and the full text. The article's PDF also carries a disclaimer stating that it is an unedited article. Subsequent production stages will simply replace this version.

Manuscripts are available online as "in press" articles after completing the publisher’s proofing process. The online release is not a draft version since it is produced after all editorial and author corrections are made; however, there is a disclaimer in case a critical error is found. No routine editing will occur once an article appears online. The "in press" designation is removed as soon as the quarterly issue is available online.

It is the corresponding author's responsibility that all editing be done at the time the original proofs are received from the publisher and that the publisher is notified immediately if the authors do not wish to have the "in press" article released online. All notifications regarding proof approvals, proof corrections, or requests that an article not be released "in press" prior to publication must come from the corresponding author and sent to Lisa Traynor ([email protected]).




If you have questions about the submission process or are unable to access the system, please contact the Editorial Office by e-mail at [email protected] or by phone at 415-447-0261.

Communication about manuscripts occur primarily through email and only with corresponding authors, so it is important for authors to keep their contact information (address, institution, phone numbers, and e-mail address) current.